1. Single Systemic Administration of a Gene Therapy Leading to Disease Treatment in Metachromatic Leukodystrophy Arsa Knock-Out Mice.
- Author
-
Martin, Thia St., Seabrook, Tania A., Gall, Katherine, Newman, Jenn, Avila, Nancy, Hayes, April, Kivaa, Monicah, Lotterhand, Jason, Mercaldi, Michael, Patel, Kruti, Rivas, Israel J., Woodcock, Stephen, Wright, Teresa L., Seymour, Albert B., Francone, Omar L., and Gingras, Jacinthe
- Subjects
- *
KNOCKOUT mice , *GENE therapy , *THERAPEUTICS , *LEUKODYSTROPHY , *TRANSGENE expression , *GLYCOGEN storage disease type II - Abstract
Metachromatic leukodystrophy (MLD) is a rare, inherited, demyelinating lysosomal storage disorder caused by mutations in the arylsulfatase-A gene (ARSA). In patients, levels of functional ARSA enzyme are diminished and lead to deleterious accumulation of sulfatides. Herein, we demonstrate that intravenous administration of HSC15/ARSA restored the endogenous murine biodistribution of the corresponding enzyme, and overexpression of ARSA corrected disease biomarkers and ameliorated motor deficits in Arsa KO mice of either sex. In treated Arsa KO mice, when compared with intravenously administered AAV9/ARSA, significant increases in brain ARSA activity, transcript levels, and vector genomes were observed with HSC15/ARSA. Durability of transgene expression was established in neonate and adult mice out to 12 and 52 weeks, respectively. Levels and correlation between changes in biomarkers and ARSA activity required to achieve functional motor benefit was also defined. Finally, we demonstrated blood-nerve, blood-spinal and blood-brain barrier crossing as well as the presence of circulating ARSA enzyme activity in the serum of healthy nonhuman primates of either sex. Together, these findings support the use of intravenous delivery of HSC15/ARSA-mediated gene therapy for the treatment of MLD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF